Batavia Biosciences BV, of Leiden, the Netherlands, received a follow-up grant of $2.2 million from the global nonprofit Path, to develop and manufacture novel oral poliovirus vaccines. 

The U.S. Court of Appeals for the Federal Circuit Friday unsealed its decision in the patent lawsuit between Enzo Life Sciences Inc. and a group of defendant-appellees led by Roche Molecular Systems Inc., affirming a lower court's decision to grant summary judgment against Enzo for lack of enablement of the disputed patent claims. 

Oncosenx Inc., of Seattle, said it raised $3 million in pre-seed funding to advance its pipeline. The company is developing a selective tumor-killing platform with two main components: a proprietary lipid nanoparticle for cellular delivery and a selective DNA payload. 

Novelion Therapeutics Inc., of Vancouver, British Columbia, received written notice from Nasdaq that it is not in compliance with the continued listing requirement to maintain minimum market value of publicly held shares of $15 million. 

Algernon Pharmaceuticals Inc., of Vancouver, British Columbia, said it expects to raise between CA$2.5 million (US$1.9 million) and CA$5 million in a best efforts public offering of an undisclosed number of units intended to support up to three phase II trials.